Belviq Recall

 

Several years ago, the FDA voted 9-5 to deny approval for Belviq to be sold in the U.S. The decision was based on concerns about the drug's cancer-promoting properties. In addition, the agency believed there was not enough data on the mammary tumors of laboratory rats exposed to the drug.

According to a study conducted by the FDA, Belviq was associated with an increased risk of cancer. The CAMELLIA-TIMI 61 trial included about 12,000 patients, and showed that patients on Belviq were about seven percent more likely to have cancer than patients taking a placebo. The results of the trial also showed that some cancer types were more common in Belviq users than in the placebo group. However, the results were based on an extremely small sample size, and were not enough to make a definitive conclusion.

Another study conducted by the FDA in 2012 looked at long-term results from a clinical trial involving 3,000 patients. The results showed that Belviq users showed a 5% drop in body weight. However, the study also showed that Belviq users were at an increased risk of developing cardiovascular problems. Similarly, Belviq users were also at an increased risk of suffering from headaches, back pain, and dizziness.

The FDA also released data indicating that the risk of developing cancer was higher among users of Belviq XR, compared to patients taking other Belviq versions. Belviq users were also more likely to have very low blood sugar levels. Similarly, the FDA warned Belviq users that the drug may cause drug dependence.

The FDA also advised Belviq users that it was time to stop taking the drug, and suggested alternative treatment options. It is important to talk to a physician before stopping treatment. The FDA also advised Belviq users to dispose of their pills in a safe manner. The FDA recommends separating the pills from the packaging, disposing them in a sealed container, and disposing them in a home trash receptacle.

Another study found that Belviq users were more likely to suffer from dry mouth. According to the FDA, Belviq users are also more likely to suffer from coughs, nausea, headaches, and back pain. However, Belviq users were also more likely to suffer from fatigue and very low blood sugar levels.

Finally, the FDA recommended that Belviq users take part in a weight loss program. The FDA found that Belviq users who participated in a weight loss program showed a reduction in their body weight and body mass index. However, the FDA noted that the benefits of Belviq were minuscule, and that the drug could cause drug dependence.

In addition to the Belviq recall, there are several Belviq cancer lawsuits pending in state courts across the country. Some have been settled, while others remain open for settlement negotiations. There are also 30 Belviq cancer lawsuits pending in federal district courts. The number of Belviq cancer lawsuits is expected to grow over the next six months. As these cases come to trial, they will likely be more numerous.